BIOCRYST PHARMACEUTICALS INC — Director's Dealing 2020

Dec 17, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK: 0000882796
Period of Report: 2020-12-15

Reporting Person: Sniecinski Megan (Chief Business Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-15	Emp. Stock Option (Right to Buy)	$8.31	A	225000	Acquired	2030-12-15	Common Stock (225000)	Direct

Footnotes

F1: Annual Employee Option Grant becomes exercisable at the rate of 25% on each of the first, second, third and fourth anniversaries of the date of grant.